EP Patent

EP2898072A1 — Restoration of the cftr function by splicing modulation

Assigned to Yissum Research Development Co of Hebrew University of Jerusalem · Expires 2015-07-29 · 11y expired

What this patent protects

The present provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, compositions comprising said oligonucleotides, kits comprising said compositions, and uses thereof. In particular, the present invention provides compositions…

USPTO Abstract

The present provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, compositions comprising said oligonucleotides, kits comprising said compositions, and uses thereof. In particular, the present invention provides compositions of oligonucleotides useful in methods for suppressing exon 10 skipping optionally in combination with additional CFTR therapeutics.

Drugs covered by this patent

Patent Metadata

Patent number
EP2898072A1
Jurisdiction
EP
Classification
—
Expires
2015-07-29
Drug substance claim
No
Drug product claim
No
Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.